Topic Editors

Department of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil
School of Microbiology, Universidad de Antioquia (UdeA), Medellín, Colombia
Proteomics Center, Mycology Laboratory, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista (UNESP), Araraquara, SP, Brazil
Clinical Mycology Laboratory, Clinical Analysis Departament, School of Pharmaceutical Sciences, Universidade Estadual Paulista (UNESP), Araraquara, Brazil
1. School of Medicine, The Federal University of Mato Grosso do Sul, Campo Grande 79070-900, MS, Brazil
2. Mycology Department, Adolfo Lutz Institute Center for Disease Control Secretary of Health, Sao Paulo 01246-000, SP, Brazil

Novel Concepts and Approaches in Neglected, Emerging and Re-Emerging Pathogens: From Environment to Patient

Abstract submission deadline
closed (20 December 2021)
Manuscript submission deadline
closed (31 March 2022)
Viewed by
17848

Topic Information

Dear Colleagues,

Infectious diseases have an important impact on public health. For centuries, they have been identified as the main causes of death and sequelae and therefore still present growing challenges for health security and human progress. Over the past few decades, infectious diseases have been significantly correlated with socioeconomic, environmental and ecological factors. The risk of the growth of neglected, emerging and re-emerging pathogens is an even greater threat. Likewise, a close relationship and changes between human, animal and environmental health ("One Health" concept) significantly influence the transmission and distribution of pathogens. Studies of these infections reveal the evolutionary properties of pathogens and their dynamic relationships, quickly adaptation to new hosts due to high rates of multiplication, mutation and selection. Understanding the processes that lead to the emergence of new pathogens can help manage emerging epidemics. The growing risk of co-infections is a major threat to patient’s lives and impacts the health systems.  The particular combination of virulence factors, including microbial biofilms, may be a species specific effect which needs to be addressed at molecular level. Molecular tools help in designing newer therapies based on interferences with biofilm formation and thus countering clinical episodes of resistance. Therefore, as the emergence of an infection is a complex and multifactorial issue, a multidisciplinary approach is required.

There is a need for new tools for investigating pathogens, in order to study the host-parasite relationships, regarding their virulence, resistance development and identification. For this purpose, new molecular technologies have launched a new era in pathogen surveillance, using new generation sequencing techniques, implementation of mass spectrometry in microbiology, metagenomic analysis and determination of antimicrobial resistance. Along the same lines, the introduction of new antisense RNA and CRISPR methodologies have made it possible to know not only the functionality of several molecules that participate in host-pathogen interactions, but also to identify new targets to design antimicrobial strategies.

Given recent developments in this field, the purpose of this Topic Board is to highlight aspects related to the novel concepts in diagnostic, molecular, epidemiology, treatment, pathogenesis, etc. and approaches in neglected, emerging and re-emerging pathogens. Then, we examine the nature and scope of emerging and re-emerging microbial threats and consider methods for their control, as well as the dynamic interactions between rapidly evolving infectious agents and changes in the environment and host behavior that provide such agents with new favorable ecological niches.

This topic may be published in the form of comprehensive reviews, original studies, and novel perspectives that address aspects of basic, translational, and applied research to develop countermeasures advance, such as surveillance tools, diagnostic tests, vaccines, and therapeutics, as well as omics tools and advances in nanotechnology in diagnostic, therapeutic and microbial research, and rational drug and vaccine projects that can support research in all the above areas.

Prof. Dr. Maria José Soares Mendes Giannini
Prof. Dr. Angel Gonzalez Marin
Dr. Ana Marisa Fusco Almeida
Dr. Caroline Barcelos Costa-Orlandi
Dr. Marcia S.C. Melhem
Topic Editors

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Journal of Fungi
jof
4.2 6.7 2015 17.1 Days CHF 2600
Microbiology Research
microbiolres
2.1 1.9 2010 16.7 Days CHF 1600
Microorganisms
microorganisms
4.1 7.4 2013 13.4 Days CHF 2700
Viruses
viruses
3.8 7.3 2009 16.1 Days CHF 2600

Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

  1. Immediately share your ideas ahead of publication and establish your research priority;
  2. Protect your idea from being stolen with this time-stamped preprint article;
  3. Enhance the exposure and impact of your research;
  4. Receive feedback from your peers in advance;
  5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (4 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
14 pages, 2062 KiB  
Article
Generated Randomly and Selected Functionally? The Nature of Enterovirus Recombination
by Fadi G. Alnaji, Kirsten Bentley, Ashley Pearson, Andrew Woodman, Jonathan Moore, Helen Fox, Andrew J. Macadam and David J. Evans
Viruses 2022, 14(5), 916; https://doi.org/10.3390/v14050916 - 28 Apr 2022
Cited by 7 | Viewed by 2750
Abstract
Genetic recombination in RNA viruses is an important evolutionary mechanism. It contributes to population diversity, host/tissue adaptation, and compromises vaccine efficacy. Both the molecular mechanism and initial products of recombination are relatively poorly understood. We used an established poliovirus-based in vitro recombination assay [...] Read more.
Genetic recombination in RNA viruses is an important evolutionary mechanism. It contributes to population diversity, host/tissue adaptation, and compromises vaccine efficacy. Both the molecular mechanism and initial products of recombination are relatively poorly understood. We used an established poliovirus-based in vitro recombination assay to investigate the roles of sequence identity and RNA structure, implicated or inferred from an analysis of circulating recombinant viruses, in the process. In addition, we used next-generation sequencing to investigate the early products of recombination after cellular coinfection with different poliovirus serotypes. In independent studies, we find no evidence for a role for RNA identity or structure in determining recombination junctions location. Instead, genome function and fitness are of greater importance in determining the identity of recombinant progeny. These studies provide further insights into this important evolutionary mechanism and emphasize the critical nature of the selection process on a mixed virus population. Full article
Show Figures

Figure 1

11 pages, 2356 KiB  
Article
Inadvertent Selection of a Pathogenic Fungus Highlights Areas of Concern in Human Clinical Practices
by Justin L. Eagan, Breanne N. Steffan, Sébastien C. Ortiz, Milton T. Drott, Gustavo H. Goldman, Christina M. Hull, Nancy P. Keller and Rafael W. Bastos
J. Fungi 2022, 8(2), 157; https://doi.org/10.3390/jof8020157 - 5 Feb 2022
Cited by 1 | Viewed by 2511
Abstract
In studying the development of tolerance to common hospital cleaners (Oxivir® and CaviCide™) in clinical isolate stocks of the emerging, multidrug-resistant yeast pathogen Candida auris, we selected for a cleaner-tolerant subpopulation of a more common nosocomial pathogen, Candida glabrata. Through [...] Read more.
In studying the development of tolerance to common hospital cleaners (Oxivir® and CaviCide™) in clinical isolate stocks of the emerging, multidrug-resistant yeast pathogen Candida auris, we selected for a cleaner-tolerant subpopulation of a more common nosocomial pathogen, Candida glabrata. Through the purification of each species and subsequent competition and other analyses, we determined that C. glabrata is capable of readily dominating mixed populations of C. auris and C. glabrata when exposed to hospital cleaners. This result suggests that exposure to antimicrobial compounds can preferentially select for low-level, stress-tolerant fungal pathogens. These findings indicate that clinical disinfection practices could contribute to the selection of tolerant, pathogenic microbes that persist within healthcare settings. Full article
Show Figures

Figure 1

13 pages, 532 KiB  
Review
Influence of Maternal Microbiome and Inflammatory Response in Preterm Birth: Recent Aspects of the Prevention of Preterm Birth
by Hee Young Cho, Sung Shin Shim, Hee Jin Park and Dong Hyun Cha
Microbiol. Res. 2022, 13(1), 1-13; https://doi.org/10.3390/microbiolres13010001 - 22 Dec 2021
Cited by 3 | Viewed by 4606
Abstract
Preterm birth (PTB) is a global health issue and one of the most challenging problems affecting 12.9 million births worldwide. PTB is a multi-etiological disease and remains incompletely understood. The major cause of PTB is infection or inflammation and disruption of the vaginal [...] Read more.
Preterm birth (PTB) is a global health issue and one of the most challenging problems affecting 12.9 million births worldwide. PTB is a multi-etiological disease and remains incompletely understood. The major cause of PTB is infection or inflammation and disruption of the vaginal microbiome, which affects the maternal immunologic response leading to PTB. The vaginal microbiome composition changes by a shift in the community are typically dominated by Lactobacillus during pregnancy. There are complex interactions between the maternal microbiome in pregnancy and the development of PTB, therefore, researchers have struggled to connect the maternal microbiome with the dysregulation of the maternal immune response in cases of PTB. The host microbiome affects alterations of the microorganisms with external stimuli such as disease, nutrition, immunity, and behavior. In this review, we discuss the complex association between the maternal microbiome and the risk of PTB and also focus on recent aspects of the prevention of PTB. Full article
Show Figures

Figure 1

18 pages, 947 KiB  
Review
Chronic Diseases Associated with Malassezia Yeast
by Abdourahim Abdillah and Stéphane Ranque
J. Fungi 2021, 7(10), 855; https://doi.org/10.3390/jof7100855 - 12 Oct 2021
Cited by 19 | Viewed by 6781
Abstract
Malassezia are a lipid-dependent basidiomycetous yeast of the normal skin microbiome, although Malassezia DNA has been recently detected in other body sites and has been associated with certain chronic human diseases. This new perspective raises many questions. Are these yeasts truly present in [...] Read more.
Malassezia are a lipid-dependent basidiomycetous yeast of the normal skin microbiome, although Malassezia DNA has been recently detected in other body sites and has been associated with certain chronic human diseases. This new perspective raises many questions. Are these yeasts truly present in the investigated body site or were they contaminated by other body sites, adjacent or not? Does this DNA contamination come from living or dead yeast? If these yeasts are alive, do they belong to the resident mycobiota or are they transient colonizers which are not permanently established within these niches? Finally, are these yeasts associated with certain chronic diseases or not? In an attempt to shed light on this knowledge gap, we critically reviewed the 31 published studies focusing on the association of Malassezia spp. with chronic human diseases, including psoriasis, atopic dermatitis (AD), chronic rhinosinusitis (CRS), asthma, cystic fibrosis (CF), HIV infection, inflammatory bowel disease (IBD), colorectal cancer (CRC), and neurodegenerative diseases. Full article
Show Figures

Figure 1

Back to TopTop